We are live on ! Find out more
PRME icon

Prime Medicine
PRME

131 hedge funds and large institutions have $188M invested in Prime Medicine in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 17

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

13% more funds holding

Funds holding: 116 → 131 (+15)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8.19% less ownership

Funds ownership: 57.24% → 49.05% (-8.2%)

29% less capital invested

Capital invested by funds: $266M → $188M (-$77.9M)

56% less call options, than puts

Call options by funds: $243K | Put options by funds: $553K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
34
Increased
39
Reduced
32
Closed
17
Calls
$243K
Puts
$553K
Net Calls
-$310K
Net Calls Change
-$2.34M

Top Buyers

Rank Fund Capital Flow
1
WHG
Westwood Holdings Group
Texas
+$1.52M
2
Walleye Capital
Walleye Capital
New York
+$1.04M
3
Goldman Sachs
Goldman Sachs
New York
+$708K
4
UBS Group
UBS Group
Switzerland
+$643K
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$599K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$4.34M
2
VPC
Vestal Point Capital
New York
-$4.14M
3
DM
Deerfield Management
New York
-$3.47M
4
APM
Avidity Partners Management
Texas
-$2.69M
5
BlackRock
BlackRock
New York
-$2.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
26
Walleye Capital
New York
$1.18M +$1.04M +295,365 +273%
N
27
Nuveen
North Carolina
$1.15M – – –
CC
28
Casdin Capital
New York
$1.07M – – –
BG
29
Bollard Group
Massachusetts
$1.05M – – –
Morgan Stanley
30
Morgan Stanley
New York
$909K +$38.2K +10,885 +4%
UBS Group
31
UBS Group
Switzerland
$637K +$643K +183,165 +523%
CCC
32
Chelsea Counsel Company
California
$545K +$379K +108,090 +137%
Two Sigma Investments
33
Two Sigma Investments
New York
$485K -$535K -152,374 -48%
VAS
34
Vestmark Advisory Solutions
Massachusetts
$460K +$75.2K +21,429 +24%
SFI
35
Susquehanna Fundamental Investments
Pennsylvania
$423K +$508K +144,719 New
ECM
36
ExodusPoint Capital Management
New York
$385K +$462K +131,732 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$378K -$702 -200 -0.2%
Fidelity International
38
Fidelity International
Bermuda
$353K -$31K -8,844 -7%
Verition Fund Management
39
Verition Fund Management
Connecticut
$302K +$228K +65,000 +169%
Jane Street
40
Jane Street
New York
$297K +$155K +44,210 +77%
Barclays
41
Barclays
United Kingdom
$285K +$45.4K +12,924 +15%
Wells Fargo
42
Wells Fargo
California
$281K -$264K -75,287 -44%
Deutsche Bank
43
Deutsche Bank
Germany
$236K -$120K -34,072 -30%
AllianceBernstein
44
AllianceBernstein
Tennessee
$222K – – –
LCS
45
Levin Capital Strategies
New York
$219K +$158K +45,000 +150%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$210K +$6.7K +1,909 +3%
AC
47
Aristides Capital
Kentucky
$206K +$247K +70,500 New
Point72 Asset Management
48
Point72 Asset Management
Connecticut
$200K +$241K +68,528 New
GAA
49
Green Alpha Advisors
Colorado
$188K +$226K +64,406 New
IEFM
50
IQ EQ Fund Management
Ireland
$177K +$114K +32,572 +116%
1
2
3 4 5

PRME Hedge Fund Activity: Q4 2024 in Review

131 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q4 2024, worth a combined $188M — down 29% from $266M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PRME positions and 17 closed out — a net gain of 17 holders — while 39 added to existing stakes and 32 trimmed.

The largest buyer was Westwood Holdings Group, adding an estimated $1.52M. The largest seller was Vanguard Group, cutting an estimated $4.34M.

  • 131 institutional investors held Prime Medicine (PRME) as of Q4 2024, up from 116 in Q3 2024.
  • Funds reported $188M of Prime Medicine stock for Q4 2024, down 29% quarter-over-quarter.
  • 34 funds opened new Prime Medicine positions in Q4 2024 and 17 closed out, a net change of +17 holders.
  • The largest Prime Medicine buyer in Q4 2024 was Westwood Holdings Group, an estimated $1.52M added.
  • The largest Prime Medicine seller in Q4 2024 was Vanguard Group, an estimated $4.34M sold.

Based on aggregated 13F filings for Q4 2024.